XPENG-INC.
29.10.2020 13:02:09 CET | Business Wire | Press release
XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, this week released its 2nd Smart Car Operations Report, following its 2nd annual Tech Day where the company unveiled its newly developed cutting edge autonomous driving and in-car smart features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005643/en/
“2020 to 2022 is a period of gaining significant momentum for the Smart EV sector which will rapidly accelerate from 2023 to 2025 and a create massive disruption to traditional ICE vehicles,” said He Xiaopeng, Chairman & CEO of XPeng.
“End-to-end R&D, data-driven capabilities and fast growth are three initiatives needed for a company to gain long-term competitive advantages and dominant market share,” Chairman He added.
At its 2nd Tech Day, XPeng launched 18 firmware OTA updates, adding 82 new features to its vehicles. The voice assistant’s average monthly utilization rate reached 99.74% and in-car navigation utilization rate achieved 92.54%, according to XPeng’s 2020 Smart Car Operations Report.
XPeng’s autonomous driving system XPILOT 3.0, planned for release in the first quarter of 2021, will provide Navigation Guided Pilot (NGP) for highways and memory auto parking for carparks. These new features address some of the major challenges for drivers in China.
Navigation Guided Pilot (NGP)
Built on XPILOT 3.0, the NGP highway solution enables autonomous driving from point A to point B. The solution will be available on all of China’s major highways with high-precision digital maps and will be the most advanced navigation guided autonomous driving system for production models in China.
The NGP system incorporates driving scenarios specific to China such as traffic cone recognition and avoidance, large truck avoidance, night overtaking reminders, faulty vehicle avoidance, and vehicle follow on congested roads. It can also handle adverse weather conditions, complex roads and locations without GPS signals.
The solution will be the only 360° dual-perception system in the industry with optimal identification of automobile surroundings with the most powerful positioning capabilities in production.
Memory Auto Parking
The XPILOT 3.0 will feature a Memory Parking functionality for parking lots. This feature will recognize side-front parking spaces and cover “the last mile” of parking with the ability to avoid obstacles, plan routes and park with extreme precision. The feature is the world's first auto parking system for production vehicles that does not require any car park modifications.
“Our core competitive advantage is our end-to-end in-house developed software for autonomous driving. In the past few years, we have developed a full range of self-developed R&D and implemented these advanced technologies into our models. There are only two auto makers in the world that have end-to-end autonomous driving capabilities and XPeng is one of them,” said XinZhou Wu, Vice President of Autonomous Driving at XPeng.
World’s first All Voice In-car System
XPeng also introduced another update of its Xmart OS operating system with the world’s first All Voice In-car System, able to deliver the majority of in-car functions. The updated system is the world’s first in-car voice system that responds to continuous driver-vehicle dialogues and is able to execute 10 voice commands every 25 seconds.
“Driver-vehicle interaction technology has evolved from physical buttons to touch screens, to today’s voice commands,” said Ji YU, Vice President of Internet at XPeng.
Xmart OS is now the world’s first open-end vehicle hardware system which allows third-party applications to access vehicle status and data to produce tailor-made infotainment. It also has a unique programmable smart lighting system where users can personalize its lighting effects in the future.
Smart Car by Numbers - 2020 Xpeng Operations Report*
XPeng’s 2nd annual Smart Car Operations Report is based on data from XPeng vehicles from Jan 1, 2020 to Sep 30, 2020. The report illustrates the Smart Cars’ most appealing aspects and how customers value smart features.
- Firmware OTA launched - 18 times in the past 20 months
- New features added - 82 items
- Voice assistant monthly average utilization rate - 99.74%
- In-car navigation utilization rate - 92.54%
Intelligence Makes Driving Easier
Driving range
- Longest distance driven by a single vehicle - 3,784 km
- Accumulative monthly mileage driven by all users - 30,300,000 km
Auto Parking
- Average monthly obstacle avoidance - 9,585 times
- Average monthly auto parking - 88,000 times
- Average time taken for auto parking - 32.3 seconds
ACC (Adaptive Cruise Control)
- Utilization rate/month – 65.59%
- Average distance driven/month – 2,286,000 km
- Distance driven/car/day – 24.6 km
LCC (Lane Centering Control)
- Utilization rate/month – 42.48%
- Distance driven/month – 1,127,000 km
- Distance driven/car/day – 21.7 km
Intelligence Makes Interaction Easier
- Voice Assistant “Xiao P” total activation - 17,910,000 times
- Intelligent recommendations provided - 4,484,000 items
- Intelligent navigation routes recommended by voice assistant - 19,170,000 routes
* Data provided by Xpeng Lab based on data from all Xpeng vehicles from 1 January 2020 to 31 September 2020.
About XPeng
XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005643/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
